Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · DEFA14A

Lantheus Holdings, Inc.

LNTHNASDAQEQUITYCurrent

SEC Filing

Filed Sep 21, 2026Accepted Sep 21, 2026, 4:08 PM EDTCIK 1521036Accession 0001193125-26-396661
Share

Company context

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Switzerland, Sweden and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.

Current securities

Recent company filings

  1. Other EventsSep 21, 2026
  2. DEFA14A filingSep 17, 2026
  3. DEFM14A filingSep 8, 2026
  4. SCHEDULE 13G filingSep 4, 2026
  5. SCHEDULE 13D filingSep 4, 2026

As-filed source

Primary evidence